LSD microdosing reduces depression scores without major side effects, clinical trial finds

University of Auckland researchers report that an 8-week, twice-weekly LSD microdosing regimen for major depressive disorder ...
Medscape

Depression Rating Scales: Am I in Remission or Not?

Zimmerman and colleagues examined how many depressed patients who scored in the remission range on the 17-item Hamilton Depression Rating Scale (HDRS) did not consider themselves to be in remission ...

FDA approves Caplyta for major depressive disorder in adults

The U.S. Food and Drug Administration has approved Caplyta (lumateperone) as an adjunctive therapy with antidepressants for ...
The Pharma Letter

Neurocrine’s depression candidate fails mid-stage study but analysis continues

US biotech Neurocrine Biosciences (Nasdaq: NBIX) said its Phase II trial of NBI-1070770 in adults with major depressive ...

Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile

Neurocrine's Phase 2 trial of NBI-1070770 in major depressive disorder missed its main goal but showed good safety and strong ...
clinicaladvisor.com

SSRIs HAVE ONSET OF EFFICACY FOR DEPRESSION AS EARLY AS ONE TO SIX WEEKS

A systematic review of 50 published randomized placebo-controlled trials of selective serotonin reuptake inhibitors (SSRIs) evaluated their onset of efficacy in a total of 10,121 adults with unipolar ...